AllergyTalk Podcast Series

AllergyTalk is a podcast designed to provide easy access to research summaries from AllergyWatch and recommendations from subject matter experts in order to bring physicians up to date in the latest advances in the field of allergy and immunology.


  • Episode 9: Updates on Asthma Epidemiology and Therapy
  • Episode 10: OIT Safety, OR anaphylaxis, and IT for Cats
  • Episode 11: Step Up Therapy in Asthma, A Therapy for Habit Cough
  • Episode 12: Changing Biologics, Mucus Vicosity, Pemphigus and Food Allergy
  • Episode 13: Delayed Drug Hypersensitivity
  • Episode 14: Co-Factors & Emerging Treatments for Anaphylaxis
  • Episode 15: Sinus Surgery & Type 2 Asthma, Long Term Peanut SLIT
  • Episode 16: Laryngeal Dysfunction in Asthma, Access to Biologics
  • Episode 17: Food Avoidance After Challenge, Stress and AIT Reactions


Learning Objectives

By participating in these podcasts, learners should be able to:

  • Provide physicians with the latest research in the field of allergy/immunology relevant to practice.
  • Provide physicians with tools and techniques to implement the latest therapy recommendations.
  • Provide physicians with the tools they need to monitor their practice and assess the implementation of therapy recommendations.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

  • Stanley Fineman, MD

Independent contractor/contracted research: Aimmune, DVB Technologies, BioCryst, Regeneron; Speaker/honorarium: Boehringer-Ingelheim, Takeda/Shire

  • Merin Kalangara (Kuruvilla), MD
  • Gerald Lee, MD
Course summary
Course opens: 
Course expires: 


    The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Please login or create an account to take this course.